图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
医药载体系统评论综述
影响因子: 2.9 5年影响因子: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN 打印: 0743-4863
ISSN 在线: 2162-660X

医药载体系统评论综述

DOI: 10.1615/CritRevTherDrugCarrierSyst.2014008285
pages 49-88

Current Nanotechnological Strategies for Effective Delivery of Bioactive Drug Molecules in the Treatment of Tuberculosis

Mandeep Kaur
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab
Tarun Garg
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
Goutam Rath
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India; Punjab Technical University, Kapurthala, Punjab, India
Amit Kumar Goyal
Department of Pharmaceutics, ISF College of Pharmacy, Moga (Punjab), India; Punjab Technical University, Kapurthala, Punjab, India

ABSTRACT

Tuberculosis (TB) has gone from being a forgotten disease to a modern and recrudescent pathology from past decades. Some clinical problems and challenges associated with conventional TB chemotherapy include poor patient compliance, longer duration of chemotherapy, lesser cell permeability, primary drug resistance, difficulty in maintaining higher drug concentrations at the infected site, and degradation of the drug before reaching the target site. Thus, newer drug delivery approaches involving micrometric or nanometric carriers are needed. These delivery systems should provide advantages over conventional systems by producing optimum effectiveness to the target site, enhanced therapeutic efficacy, uniform distribution of the drug throughout the target site, increased bioavailability and sustainability of the drug, fewer side effects, and increased patient compliance. This article reviews recent updates and fabrication of drug delivery approaches for tuberculosis chemotherapy involving vesicular drug delivery systems (liposomes, niosomes, solid lipid nanoparticles), particulate drug delivery systems (nanoparticles, microparticles, dendrimers), supramolecular drug delivery systems (polymeric micelles), specialized drug delivery systems (nanosuspensions, nanoemulsions, microemulsions, dry powders), complex conjugate drug delivery systems (ISCOMs, cyclodextrin inclusion complexes), and other carrier-based drug delivery systems in order to improve patient outcomes.